908 Devices Inc. (NASDAQ:MASS - Get Free Report) CEO Kevin J. Knopp purchased 10,000 shares of the stock in a transaction that occurred on Thursday, May 9th. The stock was acquired at an average cost of $5.83 per share, for a total transaction of $58,300.00. Following the completion of the acquisition, the chief executive officer now owns 488,981 shares in the company, valued at approximately $2,850,759.23. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.
908 Devices Price Performance
Shares of MASS stock traded up $0.05 during mid-day trading on Friday, hitting $5.81. The company had a trading volume of 77,106 shares, compared to its average volume of 179,489. The company has a market capitalization of $191.61 million, a P/E ratio of -5.38 and a beta of 1.02. The stock's 50 day moving average price is $6.38 and its 200-day moving average price is $7.06. 908 Devices Inc. has a 52-week low of $4.85 and a 52-week high of $12.51.
908 Devices (NASDAQ:MASS - Get Free Report) last issued its quarterly earnings data on Tuesday, April 30th. The company reported ($0.33) earnings per share for the quarter, beating analysts' consensus estimates of ($0.36) by $0.03. 908 Devices had a negative return on equity of 20.47% and a negative net margin of 68.57%. The firm had revenue of $9.99 million during the quarter, compared to analyst estimates of $9.29 million. During the same quarter last year, the business posted ($0.39) earnings per share. The business's quarterly revenue was up 5.3% compared to the same quarter last year. On average, equities research analysts expect that 908 Devices Inc. will post -1.11 earnings per share for the current year.
Institutional Inflows and Outflows
The most important AI company you've never heard of
From Manward Press | Ad
Because this small company solves the BIGGEST problem with Nvidia's AI chips.
Already, Amazon, Microsoft, Google and others are lining up to get this company's products.
Get the full story on this secret AI company poised for massive growth
A number of hedge funds and other institutional investors have recently modified their holdings of the company. State Board of Administration of Florida Retirement System purchased a new position in shares of 908 Devices in the 1st quarter worth $80,000. Values First Advisors Inc. boosted its stake in shares of 908 Devices by 24.5% during the third quarter. Values First Advisors Inc. now owns 16,726 shares of the company's stock valued at $111,000 after purchasing an additional 3,294 shares in the last quarter. SG Americas Securities LLC purchased a new position in shares of 908 Devices in the 4th quarter valued at approximately $133,000. Arete Wealth Advisors LLC grew its position in 908 Devices by 35.8% during the 3rd quarter. Arete Wealth Advisors LLC now owns 22,758 shares of the company's stock worth $152,000 after purchasing an additional 5,997 shares during the last quarter. Finally, New York State Common Retirement Fund increased its stake in 908 Devices by 15.3% during the 3rd quarter. New York State Common Retirement Fund now owns 70,525 shares of the company's stock valued at $470,000 after purchasing an additional 9,346 shares in the last quarter. 88.06% of the stock is currently owned by institutional investors.
908 Devices Company Profile
(
Get Free Report)
908 Devices Inc, a commercial-stage technology company, provides various purpose-built handheld and desktop mass spectrometry devices to interrogate unknown and invisible materials in life sciences research, bioprocessing, pharma/biopharma, forensics, and adjacent markets. The company's products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of solid, liquid, vapor, and aerosol materials of unknown identity; Rebel, a small desktop analyzer that provides real-time information on the extracellular environment in bioprocesses; and Maverick, an optical in-line analyzer that offers real-time monitoring and control of multiple bioprocess parameters, including glucose, lactate, and total biomass in mammalian cell cultures, as well as provides process fingerprint data to support large-scale efforts in predictive bioprocess modeling.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
